Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821049 | 1.00 | KMT2A (0.39) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL5485683 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL1819102 | 0.84 | FABP5 (0.43) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL6855032 | 0.79 | KMT2A (0.46) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL7926629 | 0.79 | KMT2A (0.46) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL12292634 | 0.76 | KMT2A (0.43) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL14438582 | 0.76 | KMT2A (0.43) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL119453 | 0.75 | FABP5 (0.52) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL30491856 | 0.74 | KMT2A (0.44) | KMT2AFABP5FABP7F10EPHX2 | |
| SCHEMBL13327274 | 0.74 | POLB (0.52) | KMT2AFABP5FABP7EPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551412-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO NEUROTROPHINES | MINERVA PATENTS SA (LU) | 2011-05-04 | — | — | EP | disclosed |
| US-7625892-B2 | Pharmaceutical compositions for the treatment of diseases related to neurotrophines | MIMETECH S.R.L. (IT) | 2009-12-01 | — | — | US | disclosed |
| US-20060069092-A1 | Pharmaceutical compositions for the treatment of diseases related to neurotrophines | MIMETECH S.R.L. (IT) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069092-A1 | Pharmaceutical compositions for the treatment of diseases related to neurotrophines | NGF, BDNF, NTRK2 | KMT2A 4828/4885FABP5 1674/4885FABP7 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.